Predictors of Respiratory Failure Development in a Multicenter Cohort of Inpatients With Cirrhosis

Author:

Bajaj Jasmohan S.1,Kamath Patrick S.2ORCID,Reddy K. Rajender3ORCID,Asrani Sumeet K.4,Keaveny Andrew P.5ORCID,Tandon Puneeta6,Duarte-Rojo Andres78ORCID,Kappus Matthew9ORCID,Verna Elizabeth10,Biggins Scott W.11,Vargas Hugo E.12ORCID,Albhaisi Somaya1ORCID,Shaw Jawaid1,Dahiya Monica6,Filipek Natalia11,Fallahzadeh Mohammad Amin4ORCID,Wegermann Kara9ORCID,Cabello Ricardo7ORCID,Bera Chinmay13ORCID,Thuluvath Paul14,Bush Brian1ORCID,Thacker Leroy R.1ORCID,Wong Florence13ORCID

Affiliation:

1. Virginia Commonwealth University and Central Virginia Veterans Healthcare System, Richmond, Virginia, USA;

2. Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA;

3. University of Pennsylvania, Philadelphia, Pennsylvania, USA;

4. Baylor University Medical Center, Dallas, Texas, USA;

5. Mayo Clinic College of Medicine and Science, Jacksonville, Florida, USA;

6. University of Alberta, Edmonton, Alberta, Canada;

7. University of Pittsburgh, Pittsburgh, Pennsylvania, USA;

8. Northwestern University, Chicago, Illinois, USA;

9. Duke University, Durham, North Carolina, USA;

10. Columbia University Medical Center, New York, New York, USA;

11. University of Washington, Seattle, Washington, USA;

12. Mayo Clinic College of Medicine and Science, Phoenix, Arizona, USA;

13. University of Toronto, Toronto, Ontario, Canada;

14. Mercy Medical Center & University of Maryland School of Medicine, Baltimore, Maryland, USA.

Abstract

INTRODUCTION: Hospitalized patients with cirrhosis can develop respiratory failure (RF), which is associated with a poor prognosis, but predisposing factors are unclear. METHODS: We prospectively enrolled a multicenter North American cirrhosis inpatient cohort and collected admission and in-hospital data (grading per European Association for the Study of Liver-Chronic Liver Failure scoring system, acute kidney injury [AKI], infections [admission/nosocomial], and albumin use) in an era when terlipressin was not available in North America. Multivariable regression to predict RF was performed using only admission day and in-hospital events occurring before RF. RESULTS: A total of 511 patients from 14 sites (median age 57 years, admission model for end-stage liver disease [MELD]-Na 23) were enrolled: RF developed in 15%; AKI occurred in 24%; and 11% developed nosocomial infections (NI). At admission, patients who developed RF had higher MELD-Na, gastrointestinal (GI) bleeding/AKI-related admission, and prior infections/ascites. During hospitalization, RF developers had higher NI (especially respiratory), albumin use, and other organ failures. RF was higher in patients receiving albumin (83% vs 59%, P < 0.0001) with increasing doses (269.5 ± 210.5 vs 208.6 ± 186.1 g, P = 0.01) regardless of indication. Admission for AKI, GI bleeding, and high MELD-Na predicted RF. Using all variables, NI (odds ratio [OR] = 4.02, P = 0.0004), GI bleeding (OR = 3.1, P = 0.002), albumin use (OR = 2.93, P = 0.01), AKI (OR = 3.26, P = 0.008), and circulatory failure (OR = 3.73, P = 0.002) were associated with RF risk. DISCUSSION: In a multicenter inpatient cirrhosis study of patients not exposed to terlipressin, 15% of patients developed RF. RF risk was highest in those admitted with AKI, those who had GI bleeding on admission, and those who developed NI and other organ failures or received albumin during their hospital course. Careful volume monitoring and preventing nosocomial respiratory infections and renal or circulatory failures could reduce this risk.

Funder

U.S. Department of Veterans Affairs

Mallinckrodt Pharmaceuticals

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Hepatology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3